By Elie Dolgin

Is Genzyme, a giant among biotechs, lacking a certain je ne sais quoi? Since its launch in 1981, the company has grown from a small, 20-person startup to the biggest biotech corporation in the Boston area, with revenues topping $4 billion annually. But the company has suffered recent setbacks, and last month, as the French drug maker Sanofi-Aventis moved in to take over Genzyme, some analysts saw the possible merger as a sign of how aggressively European pharmaceutical firms are pursuing US biotech companies.

(Click here to continue reading.)

Image Tim Perce, Wikimedia